LOSS OF HETEROZYGOSITY IN THE BRCA1 AND BRCA2 LOCUS IN BREAST CANCER
| العنوان: | LOSS OF HETEROZYGOSITY IN THE BRCA1 AND BRCA2 LOCUS IN BREAST CANCER |
|---|---|
| المؤلفون: | M. M. Tsyganov, M. K. Ibragimova, A. M. Pevzner, N. V. Litviakov |
| المصدر: | Sibirskij Onkologičeskij Žurnal, Vol 19, Iss 3, Pp 97-101 (2020) |
| بيانات النشر: | Tomsk National Research Medical Center of the Russian Academy of Sciences, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, Locus (genetics), medicine.disease_cause, Loss of heterozygosity, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, breast cancer, Internal medicine, Biopsy, medicine, skin and connective tissue diseases, Gene, RC254-282, medicine.diagnostic_test, business.industry, Microarray analysis techniques, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, personalized medicine, medicine.disease, stomatognathic diseases, 030104 developmental biology, 030220 oncology & carcinogenesis, loss of heterozygosity, brca1 and brca2 mutation in the tumor, microarray analysis, DNA microarray, Carcinogenesis, business |
| الوصف: | One of the factors of variability of malignant neoplasms is the loss of heterozygosity (LOH). The biological meaning of LOH, in relation to carcinogenesis, is associated with the inactivation of heterozygous loci of pathogenetically significant genes. Thus, the aim of this work was to study BRCA1/2 LOH in breast tumors.Material and Methods. The study included 122 patients with stage IIAIIIC breast cancer. DNA was isolated from 122 biopsy samples of tumor tissue using the QIAamp DNA mini Kit (Qiagen, Germany). To assess the status of LOH, microarray analysis was performed on high-density DNA chips from Affymetrix CytoScanTM HD Array. To process the results of microchipping, we used the Chromosome Analysis Suite 3.3 program (Affymetrix, USA).Results. The loss of heterozygosity in the BRCA1 gene was found to be associated with response to NAC. It was shown that in 59 patients LOH in the BRCA1gene was associated with an objective response to treatment (p=0.005). The presence of LOH in the studied genes was associated with a favorable prognosis. The 5-year non-metastatic survival rates were 75 % and 100 % in patients with LOH in the BRCA1 and BRCA2 genes, respectively (log-rank test: p=0.003 and p=0.05, respectively).Conclusion. The phenomenon of LOH in the BRCA1/2 genes was shown to be associated with response to NACT. BRCA1/2. Further studies are needed to evaluate the frequency of BRCA1/2 LOH after NAC for choosing and changing treatment tactics. |
| اللغة: | Russian |
| تدمد: | 2312-3168 1814-4861 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e20e6612be494c7a604597a912234e0eTest https://www.siboncoj.ru/jour/article/view/1492Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e20e6612be494c7a604597a912234e0e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23123168 18144861 |
|---|